Navigation Links
For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain
Date:12/7/2009

WALTHAM, Mass., Dec. 7 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, despite its dominance in early lines of metastatic colorectal cancer treatment, Roche/Chugai's Avastin will face increasing competition from Bristol-Myers Squibb/Eli Lilly/Merck KGaA's Erbitux in Germany, France and Spain.

The new Special European Physician & Payer Forum report entitled Metastatic Colorectal Cancer in Europe: Changing Dynamics in Light of Increasing Segmentation and New Therapeutic Options finds that more than half of surveyed oncologists in Germany, France and Spain indicate that the existence of a validated biomarker for Erbitux has decreased their prescribing of Avastin in a subpopulation of patients with metastatic colorectal cancer. Sales of Erbitux in these countries will be driven by its use to treat patients with wild-type KRAS (Kirsten rat sarcoma 2 viral oncogene) metastatic colorectal cancer. However, the existence of a validated biomarker for Erbitux has not had a significant impact on the prescribing of Avastin in Italy, which is likely due to the currently low levels of KRAS testing in this country.

"More than half of oncologists in France and Italy say they use Avastin-containing regimens as first-line treatment in patients known to have wild-type KRAS metastatic colorectal cancer, despite a valid biomarker proving the efficacy of Erbitux in this population," said Decision Resources Analyst Marcus Hoyle, B.Sc. "However, in Spain, the majority of oncologists say they use Erbitux-containing regimens in this setting, which is most likely due to the high levels of KRAS testing in Spain as compared to other countries."

The report finds that reimbursement of KRAS testing varies between the European countries surveyed. In France and Spain, KRAS testing is reimbursed but i
'/>"/>

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
3. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
4. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
5. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
8. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
9. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
10. Many Heart Attack Patients Dont Get Best Emergency Treatment
11. New Study Proves That Minimally Invasive Aneurysm Treatment Yields Successful Long-Term Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... , July 28, 2014 /PRNewswire-iReach/ -- June 28 th ... laboratory which has developed the AMAS cancer test, is making ... Chicago.  To date, the test, which is a serum-based in ... is emerging as a significant tool in the fight against ... With an estimated 17 million cancer survivors in ...
(Date:7/28/2014)...  Serco Inc., a provider of professional, technology, ... awarded a re-compete contract to support the Navy ... Medical Systems.  Serco will provide deployable medical systems ... healthcare to meet warfighter and humanitarian requirements in ... five year contract has a one-year base period ...
(Date:7/28/2014)... , July 28, 2014 Southern ... Tipton , Ph.D., President and CEO of Southern ... Controlled Release Society (CRS) for the 2014-2015 term.  ... meeting on July 12 in Chicago ... countries.  The Controlled Release Society ...
Breaking Medicine Technology:Oncolab, Inc. Exhibits Pioneering AMAS Cancer Test at AACC 2Serco Awarded $22.7 Million Contract to Support Deployable Medical Systems 2Arthur J. Tipton, Ph.D., Named President of Controlled Release Society 2Arthur J. Tipton, Ph.D., Named President of Controlled Release Society 3
... a leader in the pharmaceutical treatment of breathing-control disorders, ... Thomas J. Dietz, Ph.D., as the company,s chairman.  Dr. ... a diversified financial-holdings and services company.   ... and a director of Pacific Growth Equities, LLC, a ...
... YORK, Oct. 26, 2011 Reportlinker.com announces ... available in its catalogue: ... http://www.reportlinker.com/p0158569/Medical-Imaging-Markets-Contrast-Agents.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging The ... are continuing to grow in significance as ...
Cached Medicine Technology:Thomas Dietz, Ph.D., Elected Chairman of Galleon Pharmaceuticals 2Medical Imaging Markets: Contrast Agents 2Medical Imaging Markets: Contrast Agents 3Medical Imaging Markets: Contrast Agents 4Medical Imaging Markets: Contrast Agents 5Medical Imaging Markets: Contrast Agents 6
(Date:7/28/2014)... to treat severe chronic migraine headaches led to significant ... in patients treated at Massachusetts General Hospital (MGH). ... Surgery report that more than half of 35 patients ... had headaches associated with compression of craniofacial nerves ... team,s paper has received advance online publication in the ...
(Date:7/28/2014)... Glutamine is the most abundant single amino ... conditionally essential during times when the body undergoes large ... Immune System Support. , Having a heavy work out ... with additional glutamine may be advantageous. Glutamine supplementation may ... digestion and immune system function. Stress on the body ...
(Date:7/28/2014)... 2014 (HealthDay News) --,The more chronic medical conditions people ... may be, a new study claims. Since ... issues, scientists at Johns Hopkins Bloomberg School of Public ... why gains in life expectancy are slowing in the ... as diabetes, kidney disease and heart failure is now ...
(Date:7/28/2014)... divide unless there is enough oxygen present to support ... types circumvent this rule. Researchers at The Johns Hopkins ... cells, warning signals, enabling cancers to continue to divide ... the researchers found that lysosomes the cell,s protein ... also uncovered new evidence that certain drugs can halt ...
(Date:7/28/2014)... NY (PRWEB) July 28, 2014 The ... organization that has donated more than 200,000 books to ... 2001, announces the launch of Brooke’s Cooks, a new ... while encouraging healthy living among at-risk children and their ... will include a series of nutrition information workshops, cooking ...
Breaking Medicine News(10 mins):Health News:Non-endoscopic migraine surgery provides significant symptom relief 2Health News:Betancourt Nutrition Introduces Glutamine Plus with Sustamine® L-Alanyl-L-Glutamine 2Health News:Betancourt Nutrition Introduces Glutamine Plus with Sustamine® L-Alanyl-L-Glutamine 3Health News:Chronic Medical Conditions Can Shorten Seniors' Lives: Study 2Health News:Cell's recycling center implicated in division decisions 2Health News:Brooke Jackman Foundation Launches Brooke's Cooks, New Initiative to Promote Healthy Living Among At-Risk Youth and Their Families 2Health News:Brooke Jackman Foundation Launches Brooke's Cooks, New Initiative to Promote Healthy Living Among At-Risk Youth and Their Families 3Health News:Brooke Jackman Foundation Launches Brooke's Cooks, New Initiative to Promote Healthy Living Among At-Risk Youth and Their Families 4
... 3 Endologix, Inc. (Nasdaq: ELGX ), developer of minimally ... and Chief Executive Officer, is scheduled to present at three upcoming ... Adams 3rd Annual Cardiovascular Conference at the Nikko Hotel in San ... Event: Canaccord Adams 3rd Annual Cardiovascular Conference, ...
... after the attacks, study shows , TUESDAY, Nov. 3 (HealthDay ... asthma rates twice that of the general population, a new ... and volunteers who had spent time at Ground Zero reported ... about 4 percent of the general population. The rate of ...
... , TUESDAY, Nov. 3 (HealthDay News) -- Experts have ... healthier than regular cigarettes, and new research suggests they ... less likely to quit, even those who switch specifically ... "switching to [,light, cigarettes] for any reason ...
... NBTY, Inc. (NYSE: NTY ) ( www.NBTY.com ... announced it will web cast a conference call to review fiscal ... ), on Monday, November 9, 2009 at 4:30 PM (ET). ... results will be issued at 4:00 PM (ET) that day. , ...
... COLUMBUS, Ohio, Nov. 3 National claims and risk management ... approach to claims management that ensures medical experts are involved ... company notes that the goal of the new service is ... the duration and overall cost of workers, comp claims. Avizent ...
... ... of the Health IT Standards Committee hearing held in Washington, D.C. last week, which was ... ... Orion Health Inc. endorses and commends the efforts of the Health IT Standards Committee ...
Cached Medicine News:Health News:Endologix to Present at Three Upcoming Conferences 2Health News:World Trade Center Workers Twice as Likely to Have Asthma 2Health News:World Trade Center Workers Twice as Likely to Have Asthma 3Health News:Switch to 'Light' Cigarettes Makes Quitting Tougher 2Health News:Switch to 'Light' Cigarettes Makes Quitting Tougher 3Health News:NBTY to Web Cast Fiscal Fourth Quarter Conference Call 2Health News:Avizent's New TeamCOMP Approach Helps Ensure Lower Workers' Comp Costs and Faster Claims Resolution 2Health News:Orion Health™ Participates in Health IT Standards Committee Hearing 2Health News:Orion Health™ Participates in Health IT Standards Committee Hearing 3Health News:Orion Health™ Participates in Health IT Standards Committee Hearing 4
... The StatusFirst CHF test ... anti-NT-proBNP antibody/streptavidin solid-phase chromatographic ... a sample has been ... well, the StatusFirst CHF ...
... practices that need an ... Burdick Vision,Premier Holter System ... The Vision Premier system,adds ... a,more comprehensive list of ...
... EK-10 single-channel,electrocardiograph features a ... keypad. It provides the,necessary ... quick and,accurate diagnosis. The ... a built in handle ...
... contrast levels (high, 9.5 % and 6%) of ... is designed to detect very subtle changes in ... or due to refractive surgery. The upper two ... and acuity levels as the lower two rows; ...
Medicine Products: